-35%

Growth Hormone Research

CJC-1295 / Ipamorelin Dissolvable Strips

Name: CJC-1295 / Ipamorelin Dissolvable Strips
Brand: Helio Peptides
Price: 99.95 USD
Availability: InStock

CAS # 863288-34-0 (CJC-1295); 170851-70-4 (Ipamorelin)

This research blend pairs CJC-1295, a long-acting growth-hormone-releasing-hormone (GHRH) analog, with Ipamorelin, a selective growth-hormone secretagogue (GHS-R1a agonist). The two are frequently co-formulated in growth-hormone-axis research because their mechanisms are complementary — CJC-1295 raises baseline GHRH tone while Ipamorelin drives...

★★★★★ 4.9 · verified researchers

Quantity

Secure checkout

View COA → Request a research account →

Purity≥99% HPLC

FormDissolvable Strips

CAS863288-34-0 (CJC-1295); 170851-70-4 (Ipamorelin)

TestingISO 17025 3rd-party

Same-day dispatchorder before 4:30pm ET

Free reshipmentguaranteed delivery

ISO 17025 testedthird-party verified

Ships from the USAdiscreet & tracked

About CJC-1295 / Ipamorelin Dissolvable Strips

This research blend pairs CJC-1295, a long-acting growth-hormone-releasing-hormone (GHRH) analog, with Ipamorelin, a selective growth-hormone secretagogue (GHS-R1a agonist). The two are frequently co-formulated in growth-hormone-axis research because their mechanisms are complementary — CJC-1295 raises baseline GHRH tone while Ipamorelin drives pulsatile GH release without materially affecting cortisol or prolactin.

Format: supplied as dissolvable oral strips (30 per box) for fast, needle-free handling in the research setting. Exact per-strip potency is printed on the packaging.

Research use only — not for human or veterinary use.

Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.

This research blend pairs CJC-1295, a growth-hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective growth-hormone secretagogue — a combination frequently studied together in growth-hormone-axis research.

Supplied as dissolvable oral strips — 30 strips per box — for fast, consistent, needle-free handling in the research setting. Exact per-strip potency is printed on the packaging.

Every batch is independently tested by an ISO 17025-accredited laboratory to ≥99% purity, with a certificate of analysis on file for its exact lot.

For research use only. Not for human or veterinary consumption, diagnosis, or treatment.

Specifications

Identification

MaterialCJC-1295 / Ipamorelin Dissolvable Strips
Also searched asCJC-1295/Ipamorelin, CJC1295 Ipamorelin blend, GHRH + GHRP
Research AreaGrowth Hormone Research
PresentationDissolvable Strips
CAS Number863288-34-0 (CJC-1295); 170851-70-4 (Ipamorelin)
Molecular FormulaC152H252N44O42 (CJC-1295); C38H49N9O5 (Ipamorelin)
Molecular Weight3367.9 g/mol (CJC-1295); 711.9 g/mol (Ipamorelin)
TypeBlend of two synthetic peptides — a long-acting GHRH analog (CJC-1295) and a selective GH secretagogue (Ipamorelin)
Receptor / TargetCJC-1295: growth-hormone-releasing-hormone receptor (GHRH-R) agonist; Ipamorelin: ghrelin / GH-secretagogue receptor (GHS-R1a) agonist

Amino Acid Sequence

CJC-1295: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2; Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2

Analytical Data

Purity (HPLC)≥99%
Identity (MS)Confirmed to specification
TestingAccredited (ISO 17025) third-party laboratory
DocumentationPer-batch COA →

Key Characteristics

Molecular FormulaC152H252N44O42 (No DAC / Mod GRF 1-29)

Molecular Weight3367.9 g/mol (No DAC / Mod GRF 1-29)

CAS Number863288-34-0 (No DAC / Mod GRF 1-29)

PubChem CID56841945

Structure29-amino-acid GHRH(1-29) analog, amidated C-terminus

Receptor / TargetGHRH receptor (GHRH-R)

FormDissolvable oral strips (30 per box)

SolubilitySoluble in water and bacteriostatic water

StorageLyophilized: -20 C to -80 C, protected from light; short-term 4 C acceptable

StabilityLyophilized powder stable for extended periods frozen; reconstituted solution is less stable and should be kept refrigerated

Research Context

GHRH-receptor pharmacologyUsed as a receptor-selective probe to characterize GHRH-R binding, activation and downstream cAMP signaling in pituitary and heterologous cell systems.

Growth-hormone secretion dynamicsInvestigated as a tool for modeling pulsatile versus sustained GH release, particularly the contrast between the short-acting No DAC form and the long-acting DAC form.

Peptide stability engineeringServes as a reference example for studying how targeted amino-acid substitutions confer DPP-IV resistance and extend peptide half-life.

Endocrine-axis modelingApplied in research on the hypothalamic-pituitary GH axis and its interaction with downstream IGF-1 signaling.

Analytical method developmentUsed as a well-characterized reference peptide for HPLC and mass-spectrometry assay validation.

Research Findings

Published research on the CJC-1295 backbone has focused on the pharmacokinetic consequences of DPP-IV-resistant substitutions and albumin conjugation. Studies of the DAC-conjugated form report markedly prolonged circulating half-life relative to native GHRH, with sustained elevation of GH and IGF-1 in animal and early clinical model systems, whereas the unconjugated Mod GRF (1-29) form is characterized by rapid clearance and short, discrete secretory responses.

Comparative work in the GHRH-analog class has examined how conjugation strategy influences the amplitude and pattern of GH pulses, making CJC-1295 a frequently cited experimental system for distinguishing sustained-exposure from pulsatile GHRH-receptor stimulation.

History

CJC-1295 was developed in the early 2000s by ConjuChem Biotechnologies as part of a program applying Drug Affinity Complex technology to peptide hormones, extending GHRH(1-29) half-life by covalent conjugation to circulating albumin. The unconjugated substituted backbone (Modified GRF 1-29) subsequently became a widely used short-acting research counterpart, and both forms remain common reference tools in growth-hormone-axis studies.

References

Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
Jette L, et al. hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058.
Alba M, et al. Once-daily administration of CJC-1295, a long-acting GHRH analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294.

Cited literature refers to laboratory and preclinical research. This material is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.

Why researchers choose Helio Peptides

99%+ PurityHPLC-verified every batch

Accredited TestingIndependent ISO 17025 laboratory

Per-Batch COADocumentation tied to your lot

Made in the USADiscreet, protected shipping

Frequently Asked

Are these research materials third-party tested?

Yes — every batch is analysed by an accredited (ISO 17025) independent laboratory using HPLC and mass spectrometry, with a per-batch Certificate of Analysis.

What purity are the materials?

Materials are verified to 99%+ HPLC purity. Any batch that does not meet the threshold is not released.

Do you provide a Certificate of Analysis (COA)?

Yes. Per-batch COA documentation is provided and is traceable by lot number.

Where do you ship from?

Materials are shipped from the USA in discreet, protective packaging.

Are these products for human use?

No. All materials are sold strictly for laboratory research use only — not for human or animal consumption, diagnosis, treatment, or prevention of any disease.